drugset / Trial / NCT04886271
Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a multi-center phase II clinical trial to evaluate the anti-tumor activity and safety of HX009 in subjects with advanced solid tumors.
Timeline
- Start
- 2021-05-12
- Primary completion
- 2024-01-12
- Completion
- 2024-02-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HX009 | Protein / enzyme biologic | 5 mg/kg | Intravenous |